Viyash Scientific Ltd
Viyash Scientific Q2 FY26 earnings call: Revenue & Margins
Q2 FY26 earnings call: what management said on revenue, margins and capex.
Guidance rank: #70 of 84 in Pharmaceuticals & Biotechnology
See the sector's top 10 — free with your mobile number.
The short version
SeQuent Scientific aims for sustained double-digit revenue growth, targeting around 15% year-on-year, as demonstrated by recent quarters. Revenue Growth: SeQuent expects strong top-line growth with a 15% YoY increase in Q2 FY26 revenue; Viyash anticipates over 20% CAGR in the next 3 years.
From Viyash Scientific Ltd's Q2 FY26 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- SeQuent Scientific aims for sustained double-digit revenue growth, targeting around 15% year-on-year, as demonstrated by recent quarters.
- Formulation segment is expected to grow strongly, particularly in companion animal health, with plans to expand front-end presence in markets like Mexico and launch new products in Latin America (e.g., tulathromycin injection in Brazil).
- API business targets maintaining an INR100 crore run rate with growth expected from FY '27 onwards, supported by new production lines and increased capacity (e.g., albendazole sales growing due to site shutdowns of competitors).
- The combined entity post-merger expects robust growth driven by synergies in R&D, manufacturing optimization, and product launches, aiming for at least 20% EBITDA margin sustainability.
2 more points from Viyash Scientific Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Viyash Scientific Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Capex for API segment:
- Around INR 60 crores spent recently by Viyash.
- No major capex expected in the next 2 years for current strategic API business.
- Some capex might be required for new opportunities like CDMO and complex molecules.
- Capex for formulation segment:
- Planning to improve pet care manufacturing capability starting possibly from FY '27, spilling into FY '28.
- Expected capex of about INR 100-150 crores in FY '27-FY '28 focused on manufacturing base, predominantly in India.
- Strategic investments:
- Actively exploring inorganic opportunities—both small and large—that fit the global animal health strategy.
- Inorganic targets include front-end expansion in Europe, new product in-licensing, manufacturing base expansion in India.
2 more points from Viyash Scientific Ltd's call on capex
Create a free account to keep reading this call
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Viyash Scientific Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
See what Viyash Scientific Ltd said on order book & pipeline — free account, 30 seconds.
Viyash Scientific Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest (Q4 FY26): revenue ₹920 Cr, net profit ₹66 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Viyash Scientific's management said in earlier quarters
- Q1 FY27 earnings call analysis →
- Q4 FY26 earnings call analysis →
- Q3 FY26 earnings call analysis →
- Q4 FY26 earnings call analysis →
- Q1 FY26 earnings call →
- Q4 FY25 earnings call →
- Q3 FY25 earnings call →
- Q2 FY25 earnings call →
- Q2 FY25 earnings call →
- Q1 FY25 earnings call →
- Q4 FY24 earnings call →
- Q3 FY24 earnings call →
Others in Pharmaceuticals & Biotechnology this season
- Bajaj Healthcare (Q2 FY26)
For HYE (Half Year Ending) Sept 2025, Total Income reported is ₹299.28 crore. Key investor presentation takeaways from Bajaj Healthcare Ltd's Q2 FY26 investor p
- Infinium Pharma (Q2 FY26)
Revenue from Operations for H1FY26: Rs 84.05 crore, a 1% YoY increase from Rs 82.98 crore in H1FY25 (Page 22). Key investor presentation takeaways from Infinium
- Wanbury (Q2 FY26)
Q2FY26 Revenue from Operations: ₹160.06 Crore . Key investor presentation takeaways from Wanbury Ltd's Q2 FY26 investor presentation — and how it ranks against
- Balaxi Pharma (Q2 FY26)
Revenue for Q2 FY26: ₹56.17 crore . Key investor presentation takeaways from Balaxi Pharma's Q2 FY26 investor presentation — and how it ranks against sector pee
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Viyash Scientific Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Viyash Scientific Ltd Q2 FY26 results?
SeQuent Scientific aims for sustained double-digit revenue growth, targeting around 15% year-on-year, as demonstrated by recent quarters. Revenue Growth: SeQuent expects strong top-line growth with a 15% YoY increase in Q2 FY26 revenue; Viyash anticipates over 20% CAGR in the next 3 years.
What is Viyash Scientific Ltd share price analysis?
Viyash Scientific Ltd currently shows a neutral. The stock trades at a P/E of 50.8 with a market cap of ₹11,246 Cr. Investors should review the full earnings analysis for detailed insights.
Is Viyash Scientific Ltd planning capital expenditure?
Capex for API segment: - Around INR 60 crores spent recently by Viyash.
Keep Viyash Scientific Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.